Two Sigma Advisers
NAVB

Two Sigma Advisers’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Two Sigma Advisers’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,000
Closed -$9K – 3009
2022
Q1 		$9K Sell
12,000
-49,400
-80% -$45.3K ﹤0.01% 2701
2021
Q4 		$61K Sell
61,400
-35,700
-37% -$50.2K ﹤0.01% 2461
2021
Q3 		$170K Sell
97,100
-56,186
-37% -$94.5K ﹤0.01% 2278
2021
Q2 		$281K Buy
153,286
+25,786
+20% +$45.6K ﹤0.01% 2159
2021
Q1 		$258K Buy
127,500
+50,000
+65% +$117K ﹤0.01% 2277
2020
Q4 		$167K Buy
77,500
+36,500
+89% +$86K ﹤0.01% 2205
2020
Q3 		$111K Buy
+41,000
New +$147K ﹤0.01% 2263
2016
Q2 		– Sell
-760
Closed -$14K – 2263
2016
Q1 		$14K Buy
760
+30
+4% +$577 ﹤0.01% 2011
2015
Q4 		$19K Sell
730
-385
-35% -$13.4K ﹤0.01% 1844
2015
Q3 		$51K Buy
1,115
+530
+91% +$20K ﹤0.01% 1762
2015
Q2 		$19K Hold
585
– – ﹤0.01% 1854
2015
Q1 		$19K Buy
+585
New +$19.8K ﹤0.01% 1835

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's NAVB Position: Q2 2022 in Review

Two Sigma Advisers sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2022, closing a stake of 12,000 shares — an estimated $9K sold.

Two Sigma Advisers first reported a position in NAVB in Q1 2015 and held it in 12 quarters. The position peaked at $281K in Q2 2021. 26 funds tracked by Wall St. Rank hold NAVB as of Q2 2022.

  • Two Sigma Advisers reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 12,000 Navidea Biopharmaceuticals Inc. shares in Q2 2022, an estimated $9K.
  • Two Sigma Advisers first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2015 and held it in 12 quarters.
  • Two Sigma Advisers's Navidea Biopharmaceuticals Inc. position peaked at $281K in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.